转移性胆道癌的系统治疗：现状与未来展望。
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
机构信息
Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124 Bari, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, 40138 Bologna, Italy.
出版信息
Curr Oncol. 2022 Jan 27;29(2):551-564. doi: 10.3390/curroncol29020050.
Recent years have seen some breakthroughs in the therapeutic landscape of advanced biliary tract cancer (BTC). Firstly, a better understanding of the molecular background of BTC has led to important improvements in the management of these hepatobiliary malignancies, with the advent of targeted agents representing an unprecedented paradigm shift, as witnessed by the FDA approval of pemigatinib and infigratinib for FGFR2-rearranged and ivosidenib in IDH1-mutant cholangiocarcinoma. In addition, several novel treatments are under assessment, including immune checkpoint inhibitors and combination chemotherapies. In the current review, we provide an overview of systemic treatment for metastatic BTC, summarizing recent clinical data on chemotherapy as well as the main results of targeted therapies and immunotherapy.
近年来，在晚期胆道癌（BTC）的治疗领域取得了一些突破。首先，对 BTC 的分子背景有了更好的理解，这使得这些肝胆恶性肿瘤的治疗得到了重要的改善，靶向药物的出现代表了前所未有的范式转变，FDA 批准 pemigatinib 和 infigratinib 用于 FGFR2 重排，ivosidenib 用于 IDH1 突变胆管癌就是明证。此外，还有几种新的治疗方法正在评估中，包括免疫检查点抑制剂和联合化疗。在本综述中，我们对转移性 BTC 的系统治疗进行了概述，总结了化疗的最新临床数据以及靶向治疗和免疫治疗的主要结果。
Zotero 插件